Fujian Seaward Pharmaceutical Co., Ltd - The
Company
Fujian Seaward Pharmaceutical Company, Ltd.
(hereunder abbreviated as Fujian Seaward) is located in Jinjiang
Technology & Industry Zone of Jinjiang City, Fujian Province.
It is a solely foreign invested high-tech pharmaceutical enterprise
registered in August 2001 by China Expert (Holdings) Limited (hereunder
abbreviated as Expert Holdings), with registered capital 30 million
US dollars. Its main line of business is the research and development,
manufacturing and selling of new high-tech pharmaceutical products.
The first phase of Fujian Seaward occupies an area of 100 thousand
square meters, building area 40 thousand square meters. For 2 consecutive
years, it has been listed as Major Foreign Capital Introduction
Project in Fujian Province.
The production base began work in December 2001, and after one
year’s intense construction work, it was finished in December
2002 and passed inspection by provincial authorities in March 2003.
On November 2003, it passed overall GMP certification once through
with excellent scores.
Currently, the factory is consisted of 10 modularized workshops,
each with 11 hundred square meter area, independent ventilation
system, and can conduct multi-variety and multi-form production.
It is the biggest pharmaceutical enterprise of preparation type
in Fujian Province, and with the most advanced equipment and newest
design and construction.
Currently, three workshops are in operation, of which the production
capacity for tablets is 500 million tablets/year, that for capsules
is 200 million capsules/year, and that for granules is 50 million
bags/year. (The above production capacities are based on one shift,
and a factor of 3 should be applied to three-shift production).
Utility pipelines for the other seven workshops have already been
finished.
In view of such huge manufacturing capacity, our company is very
willing to contract manufacture all sorts of drug for other companies.
If there is demand for types other than the above three, batch production
can begin after a three months’ preparation (for workshop
fixing up and equipment installation and testing), if the production
quantity is suitable.
Currently Fujian Seaward has 15 varieties in production, of which
Nabumetone Dispersible Tablets is the only type of the same variety
in China’s market. There will be two to three new products
going to the market in this and the coming year.
Fujian Seaward is an industrial company in the medical block under
the Expert Holdings. In addition, there is a commercial company
and an R&D company in the block. The three of them together
are generally referred to as “Seaward pharmaceutical”.
Beijing Seaward Medical Company, Ltd.
(abbreviated as Beijing Seaward)
It is a purchased brand-name medicine whole-selling company in
Beijing, originally named Beijing Deshoutang, with a history of
over one hundred years. The name was changed to Beijing Seaward
Medical Company, Ltd. the end last year, and passed GSP certification
on January 2004. Through cooperation with others and self-building,
it has set up a nation wide market network with high flexibility
and broad covering. It has now established cooperative relationships
with various domestic and foreign manufacturers, and is a general
agent in China of various pharmaceutical products and medical equipments.
It has established good cooperative relationships and signed agreements
with many domestic commercial companies and terminal institutions.
We are very willing to act as general China agent of pharmaceutical
products and medical equipment on behalf of companies at home and
abroad.
Beijing Pumeishou Biomedicine & Technology Inc.
(abbreviated as Pumeishou)
It is a new drug research company through cooperation with Basic
Drug Institute of Chinese Medical Academy. The abundant expert resources
and equipment resources of the Academy and market resources of our
company will inject strong vitality to the company, and new drug
projects with bright prospect will be put into operation in Fujian
Seaward one after the other.
Seaward Pharmaceutical is a youthful yet experienced, resourceful
and vigorous team eager to learn, and as well a united and competing
one. The team’s highest behavior principle is the company’s
motto:“Respect life, be serious with quality, be meticulous,
and act promptly.” Depending on each individual,
on technological progress, and emphasizing a perfect combination
of production, market and research, Seaward Pharmaceutical is forever
increasing its Kernel competition. We desire whole-heartily to cooperate
in all possible ways with relevant enterprises in the world, to
strive together to promote progress in the pharmaceutical industry
and to contribute to the health of mankind.
Investor of Seaward Pharmaceutical—China Expert
(Holdings) Limited (www.chinaexpertnet.com) is
a high-tech service enterprise established in Hong Kong. With“integrating
expert resources and servicing the society through knowledge”as
its motto, it creates opportunities to industrialize expert high-tech
projects. It also provides full support for industrial structure
adjustment and utilizing high-tech results in the industries for
enterprises as well as for regions. It focuses on expert business,
IT business, real estate, investment and pharmaceutical industries.
It has been approved by SEC and is trading in the United States.
The Expert Holdings possesses over 20,000 top ranking experts
in all professions in the country, including about 400 academicians
of Chinese Academy and Chinese Engineering Academy, and aggregates
more than 2,000 most recent technological achievements and projects.
Of these, 300 experts are in the medical profession, and 220 projects
in high-tech medical domain.
These top national talents in China and project resources provide
full professional supports to Seaward Pharmaceutical continually.
The Expert Holdings receives attention and support from all levels
of the government and all professions in the society. On June 11th,
2000. Chairman Jiang Zemin interviewed delegates from our company,
and he put great trust and hopes on the development of the company.
|